Max Super Speciality Hospital under CCI lens

Our Bureau New Delhi | Updated on January 22, 2018 Published on November 18, 2015

The Competition Commission has ordered a probe against Max Super Speciality Hospital and medical technology company Becton Dickinson India for alleged anti-competitive practices with respect to healthcare services.

The watchdog found a prima facie case of contravention of provisions of Section 4 of the Act by the two parties and has directed its investigation arm Director General (DG) to complete the investigation within a period of 60 days.

According to the complaint filed by the informant Vivek Sharma, the two parties charged a higher MRP for disposable syringe manufactured by Becton Dickinson India and brought from an in-house pharmacy located within the hospital network of Max Super Speciality Hospital.

Becton Dickinson manufactures disposable syringe under the brand name ‘Emerald’, while Max Super Speciality Hospital is a leading multi-speciality hospital in Patparganj, New Delhi.

The CCI considered ‘provision of healthcare services by super speciality hospitals in Delhi’ as the relevant market in this case.

Published on November 18, 2015
This article is closed for comments.
Please Email the Editor